Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

Overall Status

Withdrawn

CT.gov ID

NCT00051090

Collaborator

(none)

Enrollment

Arm

Study Details

Study Description

Brief Summary

This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking telbivudine while continuing their anti-HIV drug regimen. To enroll in this study, patients must not be taking any anti-HIV drugs and cannot have taken more than 31 days of treatment with lamivudine (3TC), protease inhibitors (PIs), or nonnucleoside reverse transcriptase inhibitors (NNRTIs).

Condition or Disease	Intervention/Treatment	Phase
HIV Infections Hepatitis B	Drug: Telbivudine Drug: Lamivudine Drug: Efavirenz Drug: Didanosine Drug: Abacavir	N/A

Detailed Description

Studies indicate that 70% to 80% of HIV infected patients have or have had HBV infection and that 10% are HBV carriers. Lamivudine therapy for treatment of HBV in HIV infected patients has limited long-term efficacy due to the development of resistance mutations. Telbivudine is a thymidine analogue with excellent HBV inhibitory activity but no anti-HIV activity. The primary objective of this study is to evaluate the safety and anti-HBV activity of telbivudine alone and in combination with a lamivudine-based highly active antiretroviral therapy (HAART) regimen in patients coinfected with HBV and HIV.

Patients in this study will take telbivudine for 24 weeks. At Week 24, patients will add a HAART regimen containing lamivudine and efavirenz plus either didanosine or abacavir. Patients who are unable to add a HAART regimen at Week 24 due to lab abnormalities or other contraindications will be allowed to delay the initiation of HAART until Week 30. Patients may initiate HAART prior to Week 24 if deemed medically necessary by the primary HIV care provider. Patients will take both telbivudine and HAART for 24 weeks. At Week 48, patients will discontinue telbivudine and continue on the HAART regimen alone for an additional 12 weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A All eligible study participants	Drug: Telbivudine Administered orally at a daily dosage of 600 mg for a period of 48 weeks Drug: Lamivudine Administered orally at a total daily dosage of 300 mg for Weeks 24-48 Drug: Efavirenz Administered orally at a daily dose of 600 mg Drug: Didanosine Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight Drug: Abacavir Administered orally twice daily in doses of 300 mg

Arm

Intervention/Treatment

Experimental: A

All eligible study participants

Drug: Telbivudine

Administered orally at a daily dosage of 600 mg for a period of 48 weeks

Drug: Lamivudine

Administered orally at a total daily dosage of 300 mg for Weeks 24-48

Drug: Efavirenz

Administered orally at a daily dose of 600 mg

Drug: Didanosine

Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight

Drug: Abacavir

Administered orally twice daily in doses of 300 mg

Outcome Measures

Primary Outcome Measures

HBV viral loads [At Study entry, Week 24 and Week 48]
Safety and tolerability of telbivudine [Throughout study]

Secondary Outcome Measures

Safety and tolerability of HAART [Throughout study]
Change in ALT level [Throughout study]
HBV genetic mutation status at HBV virologic failure [Throughout study]
HIV viral load [At Study entry, Weeks 24, 48, and 60]
HBV viral load and hepatic transaminase concentrations [At Week 60]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

HIV positive
No antiretroviral therapy within 6 months prior to study entry
Less than 31 days cumulative therapy with lamivudine, a protease inhibitor, or a nonnucleoside reverse transcriptase inhibitor
Willingness to delay HAART until at least Week 24 of study
Ability to procure and initiate HAART regimen
CD4+ cell count >= 250 cells/mm3 within 60 days prior to study entry
HIV-1 RNA > 400 copies/ml within 60 days prior to study entry
Serum HBV DNA >= 1,000,000 copies/ml within 60 days prior to study entry
Positive serum hepatitis B surface antigen (HbsAG)
Acceptable methods of contraception

Exclusion Criteria:

Pregnancy or breast-feeding
Allergy, sensitivity, or intolerance to study drugs
Alcohol consumption averaging more than 1 drink/day within past 30 days
Decompensated cirrhosis
HCV antibody positive or known HCV RNA positive
HDV antibody positive
Certain medical conditions
Use of certain medications with anti-HBV activity within 90 days of study entry
Use of systemic corticosteroids within 30 days of study entry
Use of any systemic antineoplastic, immunomodulatory treatment, or radiation within 24 weeks of study entry